Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Douglas B. Tang"'
Autor:
William F. McCarthy, Nestor Sosa, Jeanne A. Norwood, Kendra Lawrence, Ana Jiménez, Max Grogl, Janet Ransom, Charles Scott, Ryan C. Adams, Mara Kreishman-Detrick, Douglas B. Tang, Peter J. Weina, Juan Miguel Pascale
Publikováno v:
PLoS neglected tropical diseases. 13(5)
Background Paromomycin-based topical treatments were shown to be effective in curing cutaneous leishmaniasis (CL) lesions caused by Leishmania major in Tunisia. Cure rates of an index lesion were approximately 80%. As a follow on, we conducted a simi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8bb1ddd9b3f5a2c5e7cfef2f36533ca
https://pubmed.ncbi.nlm.nih.gov/31048871
https://pubmed.ncbi.nlm.nih.gov/31048871
Autor:
Darapiseth Sea, Sok Somethy, Youry Se, Satharath Prom, Chanthap Lon, Worachet Kuntawunginn, Char Meng Chour, David Saunders, Eugene Soh, Douglas B. Tang, Mark C. Haigney, Pattaraporn Vanachayangkul, Sabaithip Sriwichai, Ans Timmermans, Raveewan Siripokasupkul, Jessica E. Manning, Sut-Thang Phann, Soklyda Chann, Jaranit Kaewkungwal, Michele D. Spring, Mashamon Mitprasat, Montida Auayporn, Louis R. Cantilena, Mary So, Nillawan Buathong, Paktiya Teja-Isavadharm, Charlotte A. Lanteri
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:6056-6067
Dihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered as a monthly 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d05e163c98bdc957712d15ea974a3bb1
https://doi.org/10.1128/aac.02667-14
https://doi.org/10.1128/aac.02667-14
Autor:
Sornchai Looareesuwan, Duangsuda Siriyanonda, Udomsak Silachamroon, D. Gray Heppner, Polrat Wilairatana, Srivicha Krudsood, Douglas S. Walsh, Thomas G. Brewer, Weerapong Phumratanaprapin, Douglas B. Tang
Publikováno v:
Clinical Infectious Diseases. 39:1095-1103
Background. Tafenoquine is an 8-aminoquinoline developed as a more effective replacement for primaquine. In a previous dose-ranging study in Thailand, 3 tafenoquine regimens with total doses ranging from 500 mg to 3000 mg prevented relapse of Plasmod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45cd4ad482b30b35ee127efad42f7e3b
https://doi.org/10.1086/424508
https://doi.org/10.1086/424508
Autor:
Phongsak Jarasrumgsichol, Douglas S. Walsh, Suebpong Sangkharomy, Chainarong Cherdchu, Karl H. Rieckmann, Thomas G. Brewer, Panpaka Supakalin, Theerayuth Sasiprapha, Michael D. Edstein, Douglas B. Tang, Pradith Khaewsathien, Chirapa Eamsila
Publikováno v:
The Journal of Infectious Diseases. 190:1456-1463
We assessed monthly doses of tafenoquine for preventing Plasmodium vivax and multidrug-resistant P. falciparum malaria. In a randomized, double-blind, placebo-controlled study, 205 Thai soldiers received either a loading dose of tafenoquine 400 mg (b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c355d5c2b06259e36b96fddf98f5eee0
https://doi.org/10.1086/424468
https://doi.org/10.1086/424468
Autor:
Sacared A Bodison, Robert Putnak, Douglas B. Tang, Robert R. Edelman, Bruce L. Innis, Wellington Sun, Steven S. Wasserman, Niranjan Kanesa-thasan, Kenneth H. Eckels, David W. Vaughn
Publikováno v:
The American Journal of Tropical Medicine and Hygiene. 69:48-60
Laboratory-attenuated strains of each of the four dengue serotypes previously tested as monovalent vaccines in volunteers were combined and tested for immunogenicity, safety, and reactogenicity in 16 dosage combinations. Tetravalent vaccines made usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89ccc83886676bf25e201257d1489239
https://doi.org/10.4269/ajtmh.2003.69.48
https://doi.org/10.4269/ajtmh.2003.69.48
Autor:
Bruce L. Innis, John M. Scherer, Kenneth H. Eckels, Alan D. King, Niranjan Kanesa-thasan, Robert R. Edelman, Charles H. Hoke, Douglas B. Tang, Huo-Shu H. Houng, J. Robert Putnak, Wellington Sun
Publikováno v:
The American Journal of Tropical Medicine and Hygiene. 69:24-31
Four serotypes of monovalent live attenuated dengue virus vaccine candidates were tested for reactogenicity and immunogenicity in 49 flavivirus non-immune adult human volunteers. The four monovalent candidates were then combined into a tetravalent fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d63ee525638839424ea0875b62d3a23a
https://doi.org/10.4269/ajtmh.2003.69.6_suppl.0690024
https://doi.org/10.4269/ajtmh.2003.69.6_suppl.0690024
Autor:
Colin Ohrt, Walter R. J. Taylor, Helena Picarima, Thomas L. Richie, David J. Fryauff, Trevor R. Jones, Asep Ganjar, Emiliana Tjitra, Josh Berman, Douglas B. Tang, Hasan Basri, Hendra Widjaja, Gerald S. Murphy, David J. Braitman
Publikováno v:
Antimicrobial Agents and Chemotherapy. 47:2199-2203
Drug tolerability affects compliance. We evaluated the tolerability levels of azithromycin (750-mg loading dose plus 250 mg/day; n = 148 subjects), doxycycline (100 mg/day; n = 75), and placebo ( n = 77) as prophylaxis against malaria in Indonesian a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad61d7c6cade06c290582c1243b2523f
https://doi.org/10.1128/aac.47.7.2199-2203.2003
https://doi.org/10.1128/aac.47.7.2199-2203.2003
Autor:
Douglas B. Tang, David J. Braitman, Ralf P. Brueckner, Watcharee Chokejindachai, John Horton, Thomas G. Brewer, D. Gray Heppner, Polrat Wilairatana, Parnpen Viriyavejakul, Wilbur K. Milhous, Douglas S. Walsh, Sornchai Looareesuwan, Brian G. Schuster, Dennis E. Kyle
Publikováno v:
The Journal of Infectious Diseases. 180:1282-1287
WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faa062c43e023532321e94921e3398b9
https://doi.org/10.1086/315034
https://doi.org/10.1086/315034
Autor:
G. M. Aleman, Jonathan D. Berman, M. W. Dunne, D. M. Gordon, O. B. Ragama, S. L. Andersen, G.D. Shanks, Aggrey J. Oloo, Douglas B. Tang
Publikováno v:
Clinical Infectious Diseases. 26:146-150
Azithromycin prevents malaria in animal models and early clinical trials. We determined the prophylactic efficacy of three antibiotic regimens given for 10 weeks (azithromycin, 250 mg daily; azithromycin, 1,000 mg weekly; and doxycycline, 100 mg dail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0378ad777cf51692a9e7ba13165b12c
https://doi.org/10.1086/516281
https://doi.org/10.1086/516281
Autor:
Janet S. Foster, Wendell D. Zollinger, Douglas B. Tang, E. E. Moran, Andrew F. Trofa, Joseph J. Drabick
Publikováno v:
Vaccine. 15:1144-1148
Cimetidine (CIM) is an H2-receptor antagonist with a long history of clinical use in peptic ulcer disease. In addition to its inhibitory effect upon gastric acid secretion, CIM can also block histamine-mediated immunosuppression by inhibiting H2 rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b13830e673962487823c61a6e975eeca
https://doi.org/10.1016/s0264-410x(96)00311-8
https://doi.org/10.1016/s0264-410x(96)00311-8